Latest / Boardroom Conversations with Fexingo: CEOs, Strategy, and Corporate Leadership Explained / How the Bayer Board Handled the Roundup Crisis
Transcript
- Lucas: So, Luna, if you were a board member at Bayer in 2018, the day the Monsanto deal closed, how would you have felt about that acquisition? Luna: Probably pretty good, honestly. It was a $63 billion bet on agribusiness, and it made Bayer the biggest seed and pesticide company in the world. Lucas: Right. But within a year, the first jury verdict landed in the Roundup case, and the board was staring down a legal exposure they'd inherited. That's the moment I want to dig into today. How a modern board handles a litigation crisis that could, in theory, wipe out a decade of value. Luna: And it's not just the money. It's the uncertainty. The market hates uncertainty more than it hates bad news. Lucas: Exactly. And before we go deeper, I want to mention something that helps us keep doing these conversations. If these deep dives into board decisions have, say, changed how you think about your own company's leadership, you can support the show at buy me a coffee dot com slash fexingo. It's listener support that keeps us ad-free. Luna: Yeah, it genuinely makes a difference. And it's a nice way to say thanks if you've gotten value out of episodes like this one. Lucas: So back to Bayer. The acquisition itself was already controversial. Monsanto had its defenders, sure, but it also had a history of aggressive legal tactics, and Roundup was its flagship product. The board had to have known there were risks. Luna: But they probably didn't anticipate the scale of the litigation. The first verdict awarded $289 million to a school groundskeeper, later reduced, but it was a shot across the bow. Lucas: And that verdict came in August 2018, just three months after the deal closed. Bayer's market cap dropped by billions. The board's response, though, is what I find fascinating. Instead of settling early, they initially fought every case, insisting glyphosate was safe. Luna: That's a classic playbook, right? Deny, litigate, appeal. But when the cases started stacking up, the math changed. Lucas: By 2020, they had over forty thousand plaintiffs. And the board had to make a call: keep fighting or find a global settlement. They chose to negotiate. Luna: And that led to the $10 billion settlement to resolve many of the claims. But that wasn't the end of it. Lucas: No, because the settlement excluded future claims, and some plaintiffs opted out. So the board had to set up a separate class fund for potential future diagnoses. That's not just legal strategy; that's capital allocation under extreme uncertainty. Luna: And meanwhile, the share price kept getting hammered. I think at one point it was down more than 70% from the Monsanto deal peak. Lucas: Right. And there were also shareholder lawsuits, accusing the board of misleading investors about the risks. So the board wasn't just managing the external litigation; they were defending their own decisions in court. Luna: That's the double bind. You're trying to resolve the liability, but every move you make becomes evidence in the next suit. Lucas: And then there's the governance angle. In 2020, the board replaced the CEO, Werner Baumann, with someone from inside. That's a classic move, but it also signals to the market that the board is taking responsibility without admitting fault. Luna: Did that help? I mean, you can swap the captain, but the storm is still there. Lucas: It helped a little. New leadership brought a fresh perspective on settlement strategy. But the board also had to rethink how they managed legal risk across the whole company. They started using early case assessment and more proactive settlement structures. Luna: So what can other boards learn from this? Obviously, not every company has a potential mass-tort liability on the balance sheet. Lucas: Sure, but the core lesson is about stress-testing your risk models. The Bayer board probably had a risk register that mentioned litigation risk, but did they model a scenario where forty thousand cases pile up in three years? Probably not. Luna: And stress-testing isn't just about the numbers. It's about whether you have a communication plan that doesn't sound defensive. Lucas: That's a huge point. For years, Bayer's official stance was 'glyphosate is safe, and we'll prove it in court.' Even after the settlement, they maintained that stance. But the market didn't buy it. The board eventually shifted to a more nuanced message, acknowledging the legal reality while still defending the science. Luna: It's a fine line. You don't want to admit liability, but you also can't pretend there's no risk. Lucas: Exactly. And that's where a board's judgment comes in. They have to balance the company's reputation, the legal strategy, and the financial reality. They did eventually set aside more money, and by 2021, the total settlement package was around $16 billion. That's a huge chunk of cash for any company. Luna: And some investors were calling for a breakup, thinking the litigation was dragging down the pharmaceutical side. Did the board consider that? Lucas: There were activist investors pushing for a split. But the board decided to keep the company together, arguing that the agricultural business and pharma had synergies. That was a contentious call, and it's still debated today. Luna: So, in hindsight, was the Monsanto acquisition a mistake? Or just a mispriced risk? Lucas: I think it's the latter. The board took a calculated risk on a strategic fit, but they underpriced the tail risk. And once that tail hit, they had to manage it in real time. The question for any board is: are you prepared for a risk that has a 1% chance but would cost you 50% of your market cap? Luna: And that's a question that goes beyond just Bayer. Any company with a product that could be linked to harm has to ask that. Lucas: Yeah, and I think the Bayer case is a modern masterclass in how to navigate that. Not because they did everything right, but because they made a series of hard calls under immense pressure. They settled, they changed leadership, they adapted their message. And they survived. Luna: Survived, but at a cost. The share price still hasn't fully recovered, and there's a lingering overhang of future claims. Lucas: True. But from a governance perspective, the board's job isn't to avoid all risk; it's to manage it transparently. And I think they've done that, at least after the initial fumble. The real test is whether they can finally put the Roundup saga behind them. Luna: And that's the ongoing story. As of this summer, there are still new lawsuits being filed. So the board's work isn't done. Lucas: Right. And that's something every board should note: crises don't have a clean endpoint. They fade into the background, but they never fully disappear. The question is whether the board has built the resilience to handle the next surprise. Luna: And on that note, I think we've given our listeners a lot to chew on. The Bayer board's handling of Roundup is a case study in legal risk management. Lucas: Yeah. So if you're on a board or advising one, look at your own risk register and ask: what's our Roundup? What's the tail risk we're not modeling? And if you can answer that, you're already ahead of the game.